Demographic and clinical characteristics by study group.
| Characteristic | Titanium | CFR-PEEK | P |
| Number of patients, n (%) | 42 (67.7%) | 20 (32.3%) | - |
| Age at surgery, y, mean ± SD | 63.0 ± 10.3 | 63.8 ± 15.2 | 0.813 |
| Sex, n (%) | - | ||
| Man | 26 (61.9%) | 9 (45.0%) | |
| Woman | 16 (30.10%) | 11 (55.0%) | |
| Primary tumor,a n (%) | 0.089c | ||
| Lung, osteosarcoma, stomach, and bladder | 13 (31.0) | 5 (25.0) | |
| Esophagus and pancreas | 1 (2.38) | 0 (0) | |
| Liver, gallbladder, and unidentified | 1 (2.38) | 2 (10.0) | |
| Kidney and uterus | 1 (2.38) | 4 (20.0) | |
| Rectum | 15 (35.7) | 3 (15.0) | |
| Thyroid, breast, prostate, and carcinoid tumor | 11 (26.2) | 6 (30.0) | |
| SINS, n (%) | 0.509c | ||
| 0–6 | 2 (4.80) | 0 (0) | |
| 7–12 | 27 (64.2) | 15 (75.0) | |
| 13–18 | 13 (31.0) | 5 (25.0) | |
| SINS, mean ± SD | 11.45 ± 2.36 | 11.50 ± 1.24 | 0.933 |
| CCI score, median (range) | 9.00 (3.00–11.00) | 9.00 (2.00–13.00) | 0.106d |
| Modified Tokuhashi score, mean ± SD | 8.62 ± 2.45 | 8.40 ± 2.70 | 0.376 |
| Predicted survivability,a n (%) | 0.259c | ||
| 0–6 mo | 14 (54.5) | 8 (40.0) | |
| 9–11 mo | 19 (27.3) | 11 (50.0) | |
| >11 mo | 9 (18.2) | 1 (10.0) | |
| ECOG score, n (%) | |||
| 0 | 23 (54.8) | 10 (50.0) | 0.230c |
| 1 | 13 (31.0) | 3 (15.0) | |
| 2 | 3 (7.14) | 4 (20.0) | |
| 3 | 3 (7.14) | 2 (10.0) | |
| 4 | 0 (0) | 1 (5.0) | |
| Independence,b n (%) | 0.328c | ||
| Independent | 39 (92.9) | 17 (85.0) | |
| Dependent | 3 (7.14) | 3 (15.0) | |
Abbreviations: CCI, Charlson Comorbidity Index; CFR-PEEK, carbon fiber-reinforced polyetheretherketone; ECOG, Eastern Cooperative Oncology Group; SINS, spinal instability neoplastic score.
↵a Based on modified Tokuhashi scoring system.
↵b Based on ECOG score.
↵c χ 2 test was performed.
↵d Mann-Whitney U test was performed.